StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30241% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Kymera Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Kymera Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$396.78M. For fiscal 2025 it was -$341.09M. The highest annual figure on record is -$41.38M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$341.09M–
FY2024Dec 31, 2024-$254.26M–
FY2023Dec 31, 2023-$161.97M–
FY2022Dec 31, 2022-$158.28M–
FY2021Dec 31, 2021-$98.13M–
FY2020Dec 31, 2020-$44.54M–
FY2019Dec 31, 2019-$41.38M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$145.21M–
Q2 FY2026Jun 30, 2026-$73.58M–
Q1 FY2026Mar 31, 2026-$82.13M–
Q4 FY2025Dec 31, 2025-$95.86M–
Q3 FY2025Sep 30, 2025-$90.37M–
Q2 FY2025Jun 30, 2025-$82.47M–
Q1 FY2025Mar 31, 2025-$72.38M–
Q4 FY2024Dec 31, 2024-$78.77M–
Q3 FY2024Sep 30, 2024-$70.14M–
Q2 FY2024Jun 30, 2024-$48.99M–
Q1 FY2024Mar 31, 2024-$56.37M–
Q4 FY2023Dec 31, 2023-$18.42M–
Q3 FY2023Sep 30, 2023-$56.61M–
Q2 FY2023Jun 30, 2023-$42.48M–
Q1 FY2023Mar 31, 2023-$44.45M–
Q4 FY2022Dec 31, 2022-$37.81M–
Q3 FY2022Sep 30, 2022-$44.12M–
Q2 FY2022Jun 30, 2022-$40.11M–
Q1 FY2022Mar 31, 2022-$36.25M–
Q4 FY2021Dec 31, 2021-$33.31M–
Q3 FY2021Sep 30, 2021-$27.97M–
Q2 FY2021Jun 30, 2021-$24.18M–
Q1 FY2021Mar 31, 2021-$12.68M–
Q4 FY2020Dec 31, 2020-$12.29M–
Q3 FY2020Sep 30, 2020-$7.59M–
Q2 FY2020Jun 30, 2020-$13.80M–
Q1 FY2020Mar 31, 2020-$10.86M–
Q4 FY2019Dec 31, 2019-$11.42M–

More Kymera Therapeutics figures

See a number that looks wrong?